Scarica l'app Stockscreener
1.79
2.72%
-0.05
Precedente Chiudi:
$1.84
Aprire:
$1.8
Volume 24 ore:
660.68K
Relative Volume:
0.45
Capitalizzazione di mercato:
$411.13M
Reddito:
$8.95M
Utile/perdita netta:
$-21.49M
Rapporto P/E:
-14.92
EPS:
-0.12
Flusso di cassa netto:
$-29.24M
1 W Prestazione:
+2.87%
1M Prestazione:
+4.68%
6M Prestazione:
+77.23%
1 anno Prestazione:
+173.66%
Intervallo 1D:
$1.73
$1.8294
Intervallo di 1 settimana:
$1.65
$1.90
Portata 52W:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.785 | 423.80M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.89 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.98 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
830.49 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.41 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.62 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics (LCTX) Receives Consistent Buy Rating from D. Boral Capital | LCTX Stock News - GuruFocus
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
Progress In Research Spring 2024 - Christopher & Dana Reeve Foundation
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 3.1%Here's What Happened - MarketBeat
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
Hedge Fund Moves: Can Lineage Cell Therapeutics Inc maintain sales growth2025 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Trade Report: Is Lineage Cell Therapeutics Inc a top pick in the sectorRisk Management & Verified Entry Point Detection - baoquankhu1.vn
Market Moves: Is Lineage Cell Therapeutics Inc trading at a discountShare Buyback & Long-Term Safe Investment Plans - baoquankhu1.vn
What are the future prospects of Lineage Cell Therapeutics IncJuly 2025 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Guidance Update: Will Lineage Cell Therapeutics Inc stock hit new highs in YEARMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Published on: 2026-01-25 17:25:52 - baoquankhu1.vn
Market Overview: Should I average down on Lineage Cell Therapeutics Inc stockEarnings Trend Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Cell Therapy Manufacturing Market Set for Rapid Growth Through - openPR.com
Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience - BioInformant
Aug PostEarnings: Can Lineage Cell Therapeutics Inc stock outperform in 2025 bull market - Bộ Nội Vụ
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
CEO Moves: Why Lineage Cell Therapeutics Inc stock remains a top recommendationMarket Movers & Verified Momentum Stock Alerts - Bộ Nội Vụ
What dividend safety score for Lineage Cell Therapeutics Inc. stock2025 Geopolitical Influence & Safe Entry Point Alerts - ulpravda.ru
Aug Outlook: Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
Institution Moves: How Lineage Cell Therapeutics Inc. stock trades during market volatility2025 Stock Rankings & Daily Stock Trend Reports - ulpravda.ru
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025July 2025 Breakouts & Safe Capital Growth Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 Technical Overview & Target Return Focused Picks - Улправда
Can Lineage Cell Therapeutics Inc. stock resist sector downturnsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
Will Lineage Cell Therapeutics Inc. stock deliver long term returnsTrade Signal Summary & Community Supported Trade Ideas - Улправда
Earnings Miss: Can Lineage Cell Therapeutics Inc. stock resist sector downturnsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - ulpravda.ru
CEO Change: What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 AllTime Highs & Daily Stock Trend Reports - ulpravda.ru
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - MSN
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Up 7.6%What's Next? - MarketBeat
2026 world cup injury update tips: Will Lineage Cell Therapeutics Inc. stock benefit from sector rotation2026 world cup usa national team group stage goalkeepers transition play group prediction guide - ulpravda.ru
Lineage Cell Therapeutics (LCTX) Advances Stem Cell Collaboratio - GuruFocus
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
Lineage Cell Therapeutics highlights 2025 achievements in cell therapy By Investing.com - Investing.com Nigeria
Lineage Cell Therapeutics Issues Letter to Stockholders - pharmiweb.com
Lineage Cell Therapeutics highlights 2025 achievements in cell therapy - Investing.com
Is Lineage Cell Therapeutics Inc a good long term investmentInsider Trading Compliance & Free Stay Ahead With Picks - earlytimes.in
Cell Therapy Manufacturing Market Forecast Through 2032 - openPR.com
Lineage Cell Therapeutics Reports Q3 2025 Results - MSN
Lineage Cell Therapeutics: Progress Amid Financial Challenges - MSN
EBIT per share of Lineage Cell Therapeutics, Inc. – DUS:BT3 - TradingView — Track All Markets
How Low Can Lineage Cell Therapeutics Stock Really Go? - Trefis
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Is Lineage Cell Therapeutics Inc. stock trading at a premium valuation2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Aug Wrap: Can Lineage Cell Therapeutics Inc. stock surprise with earnings upsideWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Lineage Cell Therapeutics (LCTX) officer reports RSU vesting and tax share withholding - Stock Titan
Can Lineage Cell Therapeutics Inc. stock surprise with earnings upside2025 Dividend Review & Real-Time Buy Signal Notifications - Улправда
Will Lineage Cell Therapeutics Inc. stock outperform foreign stocksPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.55%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):